Joint Clinical Trials Office
AAML18P1 Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin &Cyclophosphamide Plus VINO-CPO Maintenance in HR-RMS
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 30, 2023
A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of KRT-232 (AMG 232) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 12, 2023
A Randomized, Open-Label, Phase II Trial of Nab-paclitaxel + Gemcitabine With or Without Botensilimab (AGEN1181) in Patients With Metastatic Pancreatic Cancer Who Have Progressed on Prior 5FU + Leucovorin + Irinotecan + Oxaliplatin (FOLFIRINOX)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 13, 2023
The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 13, 2023
Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients with Sub Optimal Response After Autologous Hematopoietic Stem Cell Transplant (AHCT)
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
C-800-25: A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) for the Treatment of Advanced, Refractory Microsatellite Stable Colorectal Cancer Without Liver Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 14, 2023
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-Expressing Metastatic Castrate Resistant Prostate Cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 12, 2023
A Phase I, Open-Label, Dose-Finding Study of TVB-2640 Administered in Combination with Enzalutamide (Xtandi) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Status:
Open to Enrollment
Primary Investigator:
Date: July 14, 2023